Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.

Cancer Manag Res · 2013 · PMC3544343 · PMID 23326203

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Critical appraisal and potential role of 223 Ra in therapy of mCRPC The pivotal Phase III randomized double-blind placebo controlled ALSYMPCA trial of 223 Ra demonstrated a highly significant OS improvement in docetaxel-pretreated or docetaxel-unfit men with symptomatic bone-metastatic CRPC and a very tolerable side-effect profile.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.